Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 6, 1998 and is headquartered in Newton, MA.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.